The company, which is developing its own treatments for cancer and is also a drugs manufacturer, was bought by Canadian parent QBiogene four years ago.
The workforce at Excell is believed to be around 125 at its West Lothian plant and problems are believed to have been caused by a lack of funding.
Creditors include the Royal Bank of Scotland and an environmental control business, Thermal Transfer, the Scotsman.com reported.
The news will hit Scotland’s biotech sector hard following the demise of PPL Therapeutics last year, which cloned Dolly the Sheep, and a number of other collapses in the sector.
Steve Absolom and Will Wright from KPMG Restructuring have been appointed joint administrators to City Motor Holdings and associated companies
Partners from Johnston Carmichael have been appointed as joint administrators to Axon Well Interventions Products UK
Begbies Traynor have been appointed administrators of William Anelay Ltd, York, one of Britain’s longest-established construction and heritage restoration companies
Smith & Williamson has been appointed administrators of charity 4Children